The tyrosine kinase Yes1 is a druggable host factor of HEV
We identified the dependence of HEV on Yes1 signaling, which may contribute to the so far scarce knowledge of HEV's pathogenesis in the future. Moreover, we provide Y1KI as a novel antiviral drug candidate specifically targeting an HEV host factor.
Authors
- Rebecca Menhua Fu
- Charlotte Decker
- Maximilian K. Nocke (ORCID: https://orcid.org/0000-0003-4632-525X)
- Suzanne J. F. Kaptein (ORCID: https://orcid.org/0000-0002-7935-0219)
- Daniel Tödt (ORCID: https://orcid.org/0000-0002-3564-1014)
- Jil A Haase (ORCID: https://orcid.org/0000-0002-1206-4090)
- Eike Steinmann (ORCID: https://orcid.org/0000-0002-3654-9965)
- Viet Loan Dao Thi (ORCID: https://orcid.org/0000-0003-2293-3592)
- Volker Kinast (ORCID: https://orcid.org/0000-0002-6984-678X)
- Johan Neyts (ORCID: https://orcid.org/0000-0002-0033-7514)
- Xin Zhang (ORCID: https://orcid.org/0000-0001-8520-1060)
- Abarna Baheerathan
Institutions
- Carl von Ossietzky Universität Oldenburg (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Heidelberg University (DE)
- Rega Institute for Medical Research (BE)
- University Hospital Heidelberg (DE)
- Universitätsklinikum Erlangen (DE)
- German Center for Infection Research (DE)
- Ruhr University Bochum (DE)
- KU Leuven (BE)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1097/hc9.0000000000000553
- Citations
- 5
- Primary Topic
- Hepatitis Viruses Studies and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- Deutsches Zentrum für Infektionsforschung
- Carl von Ossietzky Universität Oldenburg
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- KU Leuven
- China Scholarship Council